Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia.

The telomere-telomerase hypothesis states that the vast majority of human tumors have a prolonged replicative life span throughout expressing telomerase, which compensates the cell division-associated loss of telomere DNA. The use of telomere length and telomerase expression as new biological markers in cancer patients requires their correlation with disease prognosis. We, therefore, correlated the mean telomere length based on a telomere restriction fragment assay and the activity of telomerase measured with a telomeric repeat amplification protocol with clinical data and overall survival in 58 patients with B cell chronic lymphocytic leukemia (B-CLL). Telomere length showed a highly inverse correlation to telomerase activity. Patients with telomeres below 6.0 kb were associated with high telomerase activity, whereas patients with a telomere length >6.0 kb generally showed low enzyme activity (P <0.001). Patients in Binet A exhibited significantly longer telomeres and had less telomerase activity than did patients in Binet B or Binet C, where significantly shorter telomeres and higher telomerase activity were observed (P=0.031). Short telomere length and high telomerase activity were significantly associated with a shorter median survival (P=0.02 and P <0.001), and telomerase activity was the most significant prognostic factor for overall survival in B-CLL (P <0.001). Our data provide evidence that telomere length, as well telomerase activity, exerts a strong impact on the survival of B-CLL patients and that telomerase activity can be used as a new prognostic marker in this disease.

[1]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[2]  D. Bowtell,et al.  Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. , 1997, Human molecular genetics.

[3]  R. Weinberg,et al.  hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization , 1997, Cell.

[4]  C B Harley,et al.  Telomerase catalytic subunit homologs from fission yeast and human. , 1997, Science.

[5]  J. Shay,et al.  The relationship between telomere length and therapy‐associated cytogenetic responses in patients with chronic myeloid leukemia , 1997, Cancer.

[6]  J. Shay,et al.  Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression , 1997, Leukemia.

[7]  A. Gazdar,et al.  Telomerase in the early detection of cancer. , 1997, Journal of clinical pathology.

[8]  C. Autexier,et al.  Telomerase and cancer: revisiting the telomere hypothesis. , 1996, Trends in biochemical sciences.

[9]  Kazuhiro Yoshida,et al.  Telomerase activity in human breast cancer and benign breast lesions: Diagnostic applications in clinical specimens, including fine needle aspirates , 1996, International journal of cancer.

[10]  G. Roos,et al.  Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas , 1996 .

[11]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[12]  M. Mandal,et al.  Cell cycle-dependent modulation of telomerase activity in tumor cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  E. Estey,et al.  Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  A. Gazdar,et al.  Telomerase activity in human breast tumors. , 1996, Journal of the National Cancer Institute.

[15]  E. K. Parkinson,et al.  Induction of tumour cell shedding into effluent venous blood breast cancer surgery. , 1996, British Journal of Cancer.

[16]  D. Broccoli,et al.  Telomerase activity in normal and malignant hematopoietic cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  et al.,et al.  The RNA component of human telomerase , 1995, Science.

[18]  J. Shay,et al.  Telomerase activity in gastric cancer. , 1995, Cancer research.

[19]  A. Gazdar,et al.  Telomerase activity in small-cell and non-small-cell lung cancers. , 1995, Journal of the National Cancer Institute.

[20]  G. Morin Is telomerase a universal cancer target? , 1995, Journal of the National Cancer Institute.

[21]  Keiko Hiyama,et al.  Correlating telomerase activity levels with human neuroblastoma outcomes , 1995, Nature Medicine.

[22]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[23]  G. Roos,et al.  Telomerase activity in vivo in human malignant hematopoietic cells. , 1994, Oncogene.

[24]  C. Harley,et al.  Telomerase activity in human ovarian carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  C B Harley,et al.  Telomere end-replication problem and cell aging. , 1992, Journal of molecular biology.

[26]  J. Steitz,et al.  Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. , 1992, The EMBO journal.

[27]  E. Blackburn,et al.  Structure and function of telomeres , 1991, Nature.

[28]  C. Harley,et al.  Telomeres shorten during ageing of human fibroblasts , 1990, Nature.

[29]  E. Cronkite,et al.  Clinical staging of chronic lymphocytic leukemia. , 1975, Blood.

[30]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[31]  C. Greider Telomere length regulation. , 1996, Annual review of biochemistry.

[32]  E. Hiyama,et al.  Alteration of telomeric repeat length in adult and childhood solid neoplasias. , 1995, International journal of oncology.

[33]  D. Cox Regression Models and Life-Tables , 1972 .